Lipoprotein apheresis

Current Opinion in Lipidology

Volumn 21, Issue 6, 2010, Pages 487-491

  Thompson, Gilbert R ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

familial hypercholesterolaemia; hypertriglyceridaemia; lipoprotein (a)

Indexed keywords

EZETIMIBE; LIPOPROTEIN; LOMITAPIDE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN INHIBITOR; NICOTINIC ACID; SIMVASTATIN; UNCLASSIFIED DRUG;

ACUTE PANCREATITIS; APHERESIS; CLINICAL TRIAL; CORONARY ARTERY DISEASE; FAMILIAL HYPERCHOLESTEROLEMIA; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; LIPOPROTEIN APHRESIS; PLASMAPHERESIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; REGISTER; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

BLOOD COMPONENT REMOVAL; CORONARY DISEASE; GREAT BRITAIN; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; HYPERTRIGLYCERIDEMIA; LIPOPROTEIN(A); PANCREATITIS, ACUTE NECROTIZING; REGISTRIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 78649390237     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e32833e13fd     Document Type: Review

References (28)

1. Kroon AA, van't Hof MA, Demacker PN, Stalenhoef AF. The rebound of lipoproteins after LDL-apheresis: kinetics and estimation of mean lipoprotein levels. Atherosclerosis 2000; 152:519-526.
2. Thompson GR, Barbir M, Davies D, et al. Efficacy criteria and cholesterol targets for LDL apheresis. Atherosclerosis 2010; 208:317-321.
3. Palcoux J-B, Atassi-Dumont M, Lefevre P, et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 2008; 12:195-201.
4. Hudgins L, Kleimann B, Scheuer A, et al. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102:1199-1204.
5. Kolansky DM, Cuchel M, Clark BJ, et al. Longitudinal evaluation and assessment of cardiovascular disease in patients in patients with homozygous familial hypercholesterolemia. Am J Cardiol 2008; 102:1438-1443.
6. Keller C. LDL-apheresis in homozygous LDL-receptor-defective familial hypercholesterolemia: the Munich xperience. AtherosclerSuppl 2009; 10:21-26.
7. Koziolek MJ, Hennig U, Zapf A, et al. Retrospective analysis of long-term lipid apheresis at a single center. Ther Aph Dial 2009; 14:143-152.
8. Schettler V, Jaeger BR, Klingel R. The German lipid apheresis registry: remaining to be established. Atheroscler Suppl 2009; 10:59-61.
9. Stefanutti C. Italian multicenter study on low-density lipoprotein apheresis: retrospective analysis (2007). Ther Aph Dial 2009; 14:79-86.
10. The Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, et al. Lipo-protein (a) concentration and the risk of coronary heart disease, stroke and nonvascular mortality. JAMA 2009; 302: 412-423.
11. Kamstrup PR, Tybjaerg-Hansen A, Steffensen R, Nordestgaard BG. Genetically elevated lipoprotein (a) and increased risk of myocardial infarction. JAMA 2009; 301:2331-2339.
12. Clark R, Peden JF, Hopewell JC, et al. Genetic variants associated with Lp(a) lipoprotein level and coronary disease. N Eng J Med 2009; 361:2518-2528.
13. Seed M, O'Connor B, Perombelon N, et al. The effect of nicotinic acid and acipimoxon lipoprotein (a) concentration and turnover. Atherosclerosis 1993; 101:61-68.
14. Knight BL, Perombelon YF, Soutar AK, et al. Catabolism of lipoprotein (a) in familial hypercholesterolaemic subjects. Atherosclerosis 1991; 87:227-237.
15. Raal FJ, Santos RD, Blom DJ, et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholestrolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:959-961.
16. Jaeger B, Richter Y, Nagel D, et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein (a) levels and prevent major adverse coronary events. Nat Clin Prac Cardiovasc Med 2009; 6:229-239.
17. Kassner U, Vogt A, Rosada A, et al. Designing a study to evaluate the effect of apheresis in patients with elevated lipoprotein (a). Atheroscler Suppl 2009; 10:85-88.
18. Tsuang W, Navaneethan U, Ruiz R, et al. Hypertriglyceridemic pancreatitis: presentation and management. Am J Gastroenterol 2009; 104:981-991.
19. Chen J-H, Yeh J-H, Lai H-W, Liao C-S. Therapeutic plasma exchange in patients with hyperlipidemic pancreatitis. World J Gastroenterol 2004; 10:2272-2274.
20. Stefanutti C, Di Giacomo S, Vivenzio A, et al. Therapeutic plasma exchange in patients with severe hypertriglyceridemia: a multicenter study. Artif organs 2009; 33:1096-1102.
21. Kyriakidis AV, Raitsiou B, Sakagianni A, et al. Management of acute severe hyperlipidemic pancreatitis. Digestion 2006; 73:259-264.
22. Ewald N, Hardt PD, Kloer H-U. Severe hypertriglyceridemia and pancreatitis: presentation and management. Curr Opin Lipidol 2009; 20:497-504.
23. Betteridge DJ, Bakowski M, Taylor KG, et al. Treatment of severe diabetic hypertriglyceridaemia by plasma exchange. Lancet 1978; 1:1368.
24. Gubensek J, Buturovic-Ponikvar J, Marn-Pernat A, et al. Treatment of hyperlpidemic acute pancreatitis with plasma exchange: a single-center experience. Ther Aph Dial 2009; 13:314-317.
25. Yeh J-H, Lee M-F, Chiu H-C. Plasmapheresis for severe lipemia: comparison of serum-lipid clearance rates for the plasma-exchange and double-filtration variants. J Clin Apheresis 2003; 18:32-36.
26. Giannini G, Valbonesi M, Morelli F, et al. Hypertriglyceridemia: apheretic treatment. Int J Artif Organs 2005; 10:1018-1024.
27. Yeh J-H, Lee M-F, Chiu H-C. Plasmapheresis for hyperlipidemic pancreatitis. J Clin Apheresis 2003; 18:181-185.
28. Steinberg W, Tenner S. Acute pancreatitis. N Eng J Med 1994; 330:1198-1210.